Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Glutaminergic Agents for Cocaine Abuse - 5

This study has been completed.
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Information provided by (Responsible Party):
Yale University Identifier:
First received: September 20, 1999
Last updated: July 24, 2013
Last verified: December 2002
The purpose of this study is to evaluate glutaminergic agents for cocaine abuse.

Condition Intervention Phase
Cocaine-Related Disorders
Drug: Nimodipine
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Glutaminergic Agents for Cocaine Abuse

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Cocaine effects

Estimated Enrollment: 0
Study Start Date: September 1994
Study Completion Date: August 1999
Primary Completion Date: August 1999 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000280

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
  More Information

Responsible Party: Yale University Identifier: NCT00000280     History of Changes
Other Study ID Numbers: NIDA-09250-5  P50DA009250  P50-09250-5 
Study First Received: September 20, 1999
Last Updated: July 24, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Antihypertensive Agents
Calcium Channel Blockers
Vasodilator Agents processed this record on October 21, 2016